A Phase 1 study of bomedemstat in participants with hepatic impairment

Study Description

A study to evaluate the effects of liver impairment on the drug bomedemstat

Study Details

Registry ID:

NCT07049939

Conditions:

Hepatic Insufficiency

Phase:

Phase 1

Target Enrollment:

9 participants

Start Date:

August 20, 2025

Age Range:

18–75 years

Healthy Volunteers:

No

Study Locations (5 sites)

• University of Miami ( Site 0003)
  Miami, FloridaUnited States, United States
• Orlando Clinical Research Center
  Orlando, FloridaUnited States, United States
• Orlando Clinical Research Center ( Site 0001)
  Orlando, FloridaUnited States, United States
• The Texas Liver Institute
  San Antonio, TexasUnited States, United States
• The Texas Liver Institute ( Site 0002)
  San Antonio, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →